CHOP is working with Australian research firm Zelda Therapeutics to conduct a study on autism and medical marijuana. By using CHOP’s research infrastructure, they’ll observe existing patients who have autism to understand the drug’s effects.
About CHOP and Zelda Therapeutics
The Children’s Hospital of Philadelphia established the first pediatric research department in the United States in 1972. Many of the staff at CHOP are also faculty members at the University of Pennsylvania, an established Ivy League university. CHOP’s breakthroughs include methods for changing sickle-shaped blood cells, the development of a balloon catheter for cardiology and the creation of vaccines for measles, mumps and rubella.
CHOP collaborates with the University of Pennsylvania to run The Center for Autism Research (CAR), which develops effective treatments, educates patients and trains future autism researchers. They employ a multidisciplinary team to cover every aspect of the disorder.
Australia’s research firm Zelda Therapeutics focuses specifically on medicinal cannabis. As a leader in medical marijuana studies, they have conducted research with establishments all over the world. They worked on a study in Chile that also concentrated on marijuana medicine for autism, so their work with CHOP isn’t their first experience with the subject.
How Did CHOP Get Here?
CHOP’s study announcement comes on the tail of Pennsylvania’s legalization of medical marijuana. The state officially legalized cannabis medicine in early 2016 and opened the official program in November 2017. Pennsylvania is the first state to count autism as a qualifying condition. They based this decision on anecdotal evidence of cannabis’ ability to help with mood regulation and sleep issues. Further research could reinforce medicinal cannabis’ ability to relieve autism symptoms.
There is plenty of anecdotal evidence showing medical marijuana’s ability to relieve autism symptoms. But researchers don’t have much empirical evidence to work with. So, they want to collect data that shows how different cannabinoids affect patients with autism. While some patients take medicine containing only CBD, others take medication with a combination of CBD and THC. The team at CHOP wants to understand why certain kinds of cannabis medicine for better for some autistic patients than others.
Athena Zuppa, M.D., director of CHOP’s Center for Clinical Pharmacology, will lead the study’s research team. The Center for Clinical Pharmacology focuses on the development of drugs rather than autism. So, Zuppa’s team will likely emphasize the study’s impact on the development of cannabis medications. No matter how they approach the study, the team will find essential data about cannabis medicine and autism.
Since this study will be an observational one, Zuppa’s team won’t provide any marijuana medicine to patients. Instead, they’ll observe patients who already use medical marijuana to relieve their symptoms. Instead of imitating treatment, they can look at existing treatments to see what already works for patients. Zuppa stated this angle could help the team also understand how parents make medication decisions for their children.
More About Medical Marijuana and Autism
Whether medical marijuana can impact the causes of autism, it could still help autistic patients needing relief. Cannabis medicine can help folks with autism take control of their treatment by relieving symptoms like:
Irritability and aggression
Regardless of someone’s treatment plan, more evidence on autism and medical marijuana can give them control of their regimen. We should also note that there doesn’t seem to be a large amount of evidence related to adults with autism and cannabis medicine. Hopefully, in the future, research will expand to cover adults trying to manage their treatment, as well.